secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001193125-25-258780
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV Technologies appoints Philina Lee to Board of Directors effective October 30, 2025
--------------------------------------------------------------------------------

- Lee replaces Daniel Soland; appointment subject to shareholder ratification at next annual meeting.
- She previously served as Chief Commercial Officer of Blueprint Medicines, leading AYVAKIT launch.
- Lee will serve on the Compensation Committee of the Board.
- She will receive an annual retainer of €100,000 plus €5,000 for committee service.
- Company now has ten board members; Lee brings biopharma commercialization experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312525258780/0001193125-25-258780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312525258780/d82861d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-258780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer